United States: Supreme Court Issues First Interpretation Of The BPCIA

The Supreme Court yesterday issued its first opinion interpreting the Biologics Price Competition and Innovation Act ("the BPCIA"), the statute which created a pathway for the approval of abbreviated applications to market biological products. The Court's unanimous opinion contained two holdings. First, the Court determined that an injunction under federal law is not available to enforce the requirement set forth in 42 U.S.C. § 262(l)(2)(A) that a biosimilar applicant provide a reference product sponsor with a copy of its biosimilar application and manufacturing information. Second, the Court determined that a biosimilar applicant need not wait until its product is licensed by FDA to provide the reference product sponsor with notice of commercial marketing under 42 U.S.C. § 262(l)(8)(A).

On July 7, 2014, FDA notified Sandoz Inc. ("Sandoz") that Sandoz's biosimilar application referencing Neupogen® (filgrastim)—a blockbuster biologic marketed by Amgen Inc. ("Amgen")—had been accepted for review. On July 8, 2014, Sandoz notified Amgen that its biosimilar application had been accepted for review and that it intended to market its biosimilar product immediately upon FDA approval. Sandoz did not provide Amgen with a copy of its biosimilar application and manufacturing information on July 8, 2014, and it later represented to Amgen that it did not intend to provide the same to Amgen.

In October 2014, Amgen sued Sandoz for patent infringement. Amgen also asserted two claims under California's unfair competition law. Amgen sought an injunction to require Sandoz to provide it with a copy of Sandoz's biosimilar application and manufacturing information as stated in 42 U.S.C. § 262(l)(2).1 Amgen also sought an injunction to require Sandoz to provide notice of commercial marketing only after Sandoz's product became licensed by FDA.2 Sandoz counterclaimed for declaratory judgments that the asserted patents were invalid and not infringed and that it had not violated the provisions of the BPCIA.

The United States District Court for the Northern District of California granted partial judgment on the pleadings to Sandoz on its BPCIA-related counterclaims and dismissed Amgen's state law claims with prejudice. Amgen Inc. v. Sandoz Inc., No. 14-cv-04741, 2015 U.S. Dist. LEXIS 34537, at *33–35 (N.D. Cal. Mar. 19, 2015). A divided United States Court of Appeals for the Federal Circuit affirmed in part, vacated in part, and remanded. Amgen Inc. v. Sandoz Inc., 794 F.3d 1347, 1351 (Fed. Cir. 2015). The Federal Circuit: (1) affirmed the district court's dismissal of Amgen's state law claims; (2) affirmed the district court's determination that a biosimilar applicant does not have to comply with the disclosure requirement of 42 U.S.C. § 262(l)(2)(A); and (3) reversed the district court's conclusion that notice of commercial marketing may be given prior to licensure of a biosimilar product. Id. at 1354–61.

The Supreme Court vacated in part and reversed in part the judgment of the Federal Circuit. Sandoz Inc. v. Amgen Inc., Nos. 15-1039, 15-1195, slip op. at 18 (U.S. June 12, 2017) ("Slip Op."). The cases were remanded to determine whether California law would treat noncompliance with the BPCIA as "unlawful." Id.

On the first issue, the Supreme Court held that federal law does not provide an injunction to enforce the BPCIA's requirement for the biosimilar applicant to provide the reference product sponsor with its application and manufacturing information. Here, the Court generally agreed with the Federal Circuit, "though for slightly different reasons." Slip Op. at 10. The Supreme Court explained that the submission of a biosimilar application is an artificial act of infringement under 35 U.S.C. § 271(e)(2)(C), and the only remedies available for such infringement are provided at 35 U.S.C. § 271(e)(4). Id. at 12. A biosimilar applicant's failure to provide the disclosure under 42 U.S.C. §262(l)(2)(A) is not an act of infringement, and 35 U.S.C. § 271(e)(4) does not provide a remedy for that failure. Id. Rather, 42 U.S.C. § 262(l)(9)(C) provides the remedy for a biosimilar applicant's failure to disclose its application and manufacturing information to the sponsor—that is, the ability of the reference product sponsor alone to immediately bring an action on any patent that claims the biological product or its use. Id. And the declaratory judgment remedy provided in 42 U.S.C. § 262(l)(9)(C) "excludes all other factual remedies, including injunctive relief." Id. The Supreme Court concluded that "[t]he presence of [42 U.S.C.] § 262(l)(9)(C), coupled with the absence of any other textually specified remedies, indicates that Congress did not intend [reference product] sponsors to have access to injunctive relief, at least as a matter of federal law, to enforce the disclosure requirement." Id. at 13.

The Court also explained that statutory context confirmed its interpretation. Slip Op. at 13. The BPCIA provides for injunctive relief where there is a violation or threatened violation of the rules governing the confidentiality of information disclosed under 42 U.S.C. § 262(l). Id. (citing 42 U.S.C. § 262(l)(1)(H)). Thus, in the Court's view, Congress acted intentionally when it provided an injunctive remedy for breach of confidentiality requirements but did not provide the same for a breach of the disclosure requirement of 42 U.S.C. § 262(l)(2)(A). Id.

On the second issue, the Supreme Court concluded that a biosimilar applicant may provide notice of commercial marketing either before or after receiving FDA approval based on the plain language of the statute. Slip Op. at 15–16. 42 U.S.C. § 262(l)(8)(A) states that the biosimilar applicant "shall provide notice to the reference product sponsor not later than 180 days before the date of the first commercial marketing of the biological product licensed under subsection (k)." The Court reasoned that the phrase "of the biological product licensed under subsection (k)" modifies "commercial marketing" and not "notice." Id. at 16. The Court explained that the use of the word "licensed" in the statute "reflects that fact that, on the date of first commercial marketing,' the product must be 'licensed.'" Id.

The Court also explained that statutory context confirmed its interpretation. Slip Op. at 16. 42 U.S.C. § 262(l)(8)(A) contains only one timing requirement, i.e., the biosimilar applicant must provide notice at least 180 days prior to marketing its biosimilar. Id. This stands in contrast to 42 U.S.C. § 262(l)(8)(B), which imposes two timings requirements: "After receiving notice under subparagraph (a) and before such date of the first commercial marketing of such biological product, the reference product sponsor may seek a preliminary injunction." Id. Thus, the court reasoned, "'[h]ad Congress intended to' impose two timing requirements in § 262(l)(8)(A), 'it presumably would have done so expressly as it did in the immediately following' subparagraph." Id. (quoting Russello v. United States, 464 U.S. 16, 23 (1983)).

Justice Breyer joined the Court's opinion, but he wrote separately to note the fact that the FDA "may well have authority to depart from, or to modify, [the Court's] interpretation" if it "determines that a different interpretation would better serve the statute's objectives." Slip Op. at 1 (Breyer, J., concurring).


1 42 U.S.C. § 262(1)(2) provides:
(2) Subsection (k) application information Not later than 20 days after the Secretary notifies the subsection (k) applicant that the application has been accepted for review, the subsection (k) applicant—
(A) shall provide to the reference product sponsor a copy of the application submitted to the Secretary under subsection (k), and such other information that describes the process or processes used to manufacture the biological product that is the subject of such application; and
(B) may provide to the reference product sponsor additional information requested by or on behalf of the reference product sponsor.

2 42 U.S.C. § 262(1)(8)(A) provides:
(A) Notice of commercial marketing The subsection (k) applicant shall provide notice to the reference product sponsor not later than 180 days before the date of the first commercial marketing of the biological product licensed under subsection (k).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.